Marketing Campaign
0102030405
🔬 Cu-64 Cyclotron Production: Bridging Imaging and Targeted Therapy
2026-03-30
In precision medicine, nuclear medicine is evolving from diagnosis toward theranostics — integrating imaging and therapy.
👉 Copper-64 (Cu-64) is one of the most promising radionuclides in this field.
⚛️ What makes Cu-64 unique?
With a half-life of ~12.7 hours, Cu-64 offers a balance between short-lived and long-lived isotopes:
• Longer imaging window than ¹⁸F
• Higher efficiency than long-lived isotopes
More importantly, it enables dual functionality:
• β⁺ emission → PET imaging
• β⁻ / Auger electrons → therapeutic potential
👉 This makes Cu-64 a true theranostic radionuclide.
🧬 Wide applicability
Cu-64 can be used across multiple targeting strategies:
• Small molecules
• Peptides
• Monoclonal antibodies
Applications include tumor imaging, target evaluation, and drug development.
⚙️ Cyclotron-based production
Cu-64 is typically produced via cyclotron solid target irradiation (e.g., ⁶⁴Ni targets).
In practice, production is not just about irradiation — it requires a complete workflow:
• Target preparation
• Stable irradiation
• Separation & purification
• Material recovery
👉 Each step affects yield, purity, and consistency.
🏭 Why production is challenging
In practice, “can produce” ≠ “can reliably supply.”
Cu-64 production demands:
• High-quality target preparation
• Stable beam operation
• Efficient radiochemistry
👉 Only integrated systems can ensure stable output.
🔧 How LBT supports Cu-64 production
LBT provides integrated solutions including:
• Cyclotron systems (LB-11MTS / LB-20)
• Solid target systems
• Radiochemistry modules
• Automated workflows
👉 Supporting reliable, safe, and reproducible production.
💡 Looking ahead
Cu-64 is more than a PET isotope —
👉 it is a bridge between diagnosis and therapy, supporting the future of precision medicine.